Management of hyperthyroidism due to Graves’ disease: frequently asked questions and answers (if any)

L. Bartalena, L. Chiovato, P. Vitti

Research output: Contribution to journalReview articlepeer-review

Abstract

Graves’ disease is the most common cause of hyperthyroidism in iodine-replete areas. Although progress has been made in our understanding of the pathogenesis of the disease, no treatment targeting pathogenic mechanisms of the disease is presently available. Therapies for Graves’ hyperthyroidism are largely imperfect because they are bound to either a high rate of relapsing hyperthyroidism (antithyroid drugs) or lifelong hypothyroidism (radioiodine treatment or thyroidectomy). Aim of the present article is to offer a practical guidance to the reader by providing evidence-based answers to frequently asked questions in clinical practice.

Original languageEnglish
Pages (from-to)1105-1114
Number of pages10
JournalJournal of Endocrinological Investigation
Volume39
Issue number10
DOIs
Publication statusPublished - Oct 1 2016

Keywords

  • Agranulocytosis
  • Alemtuzumab
  • Childhood
  • Graves’ disease
  • Graves’ orbitopathy
  • Hyperthyroidism
  • Methimazole
  • Pregnancy
  • Propylthiouracil
  • Radioiodine
  • Thionamides
  • Thyroidectomy

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Fingerprint Dive into the research topics of 'Management of hyperthyroidism due to Graves’ disease: frequently asked questions and answers (if any)'. Together they form a unique fingerprint.

Cite this